ArticleBMC cancer2023

Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial.

Jinsong Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.